In particular, the inhibition of the IL-8/CXCR1/2 axis efficiently targets the CSC compartment in pancreatic cancer [78], and the combination of repertaxin, an antagonist of the CXCR1 receptor, with lapatinib, a tyrosine kinase inhibitor that halts HER2-mediated signaling, impairs mammosphere formation by HER2-positive cancer cells more efficiently than repertaxin or lapatinib monotherapy [79]. This evidence concerns the gene ERBB2 and cancer.